SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Men in a laboratory microscope with microscope slide in hand. A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The study, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback